Literature DB >> 22167620

Bone morphogenetic protein 4 (BMP4) is required for migration and invasion of breast cancer.

Dan Guo1, Jiayi Huang, Jianping Gong.   

Abstract

Bone-morphogenetic proteins (BMPs) play an important role in development and many cellular processes. However, their functional role in the development and progression of breast cancer is not clearly understood. In the present study, we performed a systematic expression analysis of the 14 types of BMPs in 10 human breast cancer cell lines. We found that bone morphogenetic protein 4 (BMP4) was one of the most frequently expressed BMPs. Furthermore, the expression level of BMP4 was maybe correlated with the metastatic potential of the cancer lines. Accordingly, overexpression of BMP4 in the breast cancer cell lines MCF-7 and MBA-MD-231 promoted the migration and invasion phenotypes of the cancer cells, whereas RNAi-mediated knockdown of BMP4 expression inhibited the migration and invasion activities of the cancer cells. To identify the important factors that may mediate the BMP4 functions in breast cancer cells, we analyzed a panel of cancer-related genes, and found that the expression of matrix metalloproteinase-1 (MMP-1) and C-X-C chemokine receptor type 4 (CXCR4) sharply increased at both the mRNA and protein levels in the breast cancer cells overexpressing BMP4. Interestingly, when breast cancer cells MDA-MB-231 or MCF-7 were co-cultured with the osteoblast-like cells MG63 to mimic a bone metastasis microenvironment, BMP4 did not exhibit any significant effect on the expression of OPG or RANKL, two important factors in bone remodeling. BMPs antagonists, Noggin, parallel inhibited breast cancer cell migration and invasion and induced bone remodeling. Taken together, our results strongly suggest that BMP4 may promote the migration and invasion of breast cancer cells, at least in part by up-regulating the expressions of MMP-1 and CXCR4. It is conceivable that novel therapeutics for breast cancer may be developed by targeting BMP4 signaling pathway and/or its important downstream mediators in breast cancer cells.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22167620     DOI: 10.1007/s11010-011-1170-1

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  56 in total

1.  Osteogenic activity of the fourteen types of human bone morphogenetic proteins (BMPs).

Authors:  Hongwei Cheng; Wei Jiang; Frank M Phillips; Rex C Haydon; Ying Peng; Lan Zhou; Hue H Luu; Naili An; Benjamin Breyer; Pantila Vanichakarn; Jan Paul Szatkowski; Jae Yoon Park; Tong-Chuan He
Journal:  J Bone Joint Surg Am       Date:  2003-08       Impact factor: 5.284

Review 2.  Matrix metalloproteinases (MMPs) in health and disease: an overview.

Authors:  Charles J Malemud
Journal:  Front Biosci       Date:  2006-05-01

3.  Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions.

Authors:  Brian T Feeley; Lucie Krenek; Nancy Liu; Wellington K Hsu; Seth C Gamradt; Edward M Schwarz; Johnny Huard; Jay R Lieberman
Journal:  Bone       Date:  2005-08-26       Impact factor: 4.398

4.  A comprehensive expression survey of bone morphogenetic proteins in breast cancer highlights the importance of BMP4 and BMP7.

Authors:  Emma-Leena Alarmo; Tuula Kuukasjärvi; Ritva Karhu; Anne Kallioniemi
Journal:  Breast Cancer Res Treat       Date:  2006-09-21       Impact factor: 4.872

5.  Overexpression of CXCR4 in primary tumor of patients with HER-2 negative breast cancer was predictive of a poor disease-free survival: a validation study.

Authors:  Jason Mizell; Mark Smith; Benjamin D L Li; Fred Ampil; Quyen D Chu
Journal:  Ann Surg Oncol       Date:  2009-07-11       Impact factor: 5.344

6.  Bone morphogenetic protein signaling enhances invasion and bone metastasis of breast cancer cells through Smad pathway.

Authors:  Y Katsuno; A Hanyu; H Kanda; Y Ishikawa; F Akiyama; T Iwase; E Ogata; S Ehata; K Miyazono; T Imamura
Journal:  Oncogene       Date:  2008-07-28       Impact factor: 9.867

7.  Activity of MMP-2 and MMP-9 in sera of breast cancer patients.

Authors:  Sandra Stankovic; Gordana Konjevic; Kristina Gopcevic; Viktor Jovic; Momcilo Inic; Vladimir Jurisic
Journal:  Pathol Res Pract       Date:  2010-01-25       Impact factor: 3.250

8.  Bone morphogenetic proteins induce the expression of noggin, which limits their activity in cultured rat osteoblasts.

Authors:  E Gazzerro; V Gangji; E Canalis
Journal:  J Clin Invest       Date:  1998-12-15       Impact factor: 14.808

9.  Overexpression of matrix-metalloproteinase-9 in human breast cancer: a potential favourable indicator in node-negative patients.

Authors:  A Scorilas; A Karameris; N Arnogiannaki; A Ardavanis; P Bassilopoulos; T Trangas; M Talieri
Journal:  Br J Cancer       Date:  2001-06-01       Impact factor: 7.640

10.  BMP-6 promotes E-cadherin expression through repressing deltaEF1 in breast cancer cells.

Authors:  Shuang Yang; Jun Du; Zhaoqi Wang; Wei Yuan; Yuhuan Qiao; Ming Zhang; Jie Zhang; Songyuan Gao; Jian Yin; Baocun Sun; Tianhui Zhu
Journal:  BMC Cancer       Date:  2007-11-13       Impact factor: 4.430

View more
  37 in total

1.  Regulation of stem cells-related signaling pathways in response to doxorubicin treatment in Hs578T triple-negative breast cancer cells.

Authors:  Oana Tudoran; Olga Soritau; Loredana Balacescu; Simona Visan; Otilia Barbos; Roxana Cojocneanu-Petric; Ovidiu Balacescu; Ioana Berindan-Neagoe
Journal:  Mol Cell Biochem       Date:  2015-07-18       Impact factor: 3.396

Review 2.  Beyond adiponectin and leptin: adipose tissue-derived mediators of inter-organ communication.

Authors:  Jan-Bernd Funcke; Philipp E Scherer
Journal:  J Lipid Res       Date:  2019-06-17       Impact factor: 5.922

3.  Inhibition of bone morphogenetic protein signaling reduces viability, growth and migratory potential of non-small cell lung carcinoma cells.

Authors:  Jelena Mihajlović; Laura A M Diehl; Andreas Hochhaus; Joachim H Clement
Journal:  J Cancer Res Clin Oncol       Date:  2019-09-17       Impact factor: 4.553

Review 4.  Starvation and Pseudo-Starvation as Drivers of Cancer Metastasis through Translation Reprogramming.

Authors:  Custodia García-Jiménez; Colin R Goding
Journal:  Cell Metab       Date:  2018-12-20       Impact factor: 27.287

5.  Mesenchymal stem cells from human fat engineered to secrete BMP4 are nononcogenic, suppress brain cancer, and prolong survival.

Authors:  Qian Li; Olindi Wijesekera; Sussan J Salas; Joanna Y Wang; Mingxin Zhu; Colette Aprhys; Kaisorn L Chaichana; David A Chesler; Hao Zhang; Christopher L Smith; Hugo Guerrero-Cazares; Andre Levchenko; Alfredo Quinones-Hinojosa
Journal:  Clin Cancer Res       Date:  2014-05-01       Impact factor: 12.531

6.  Downregulation of the transcription factor, FoxD3, is associated with lymph node metastases in invasive ductal carcinomas of the breast.

Authors:  Hua Zhao; Daozhen Chen; Jiayuan Wang; Yongxiang Yin; Qiong Gao; Ye Zhang
Journal:  Int J Clin Exp Pathol       Date:  2014-01-15

7.  The E2F transcription factors regulate tumor development and metastasis in a mouse model of metastatic breast cancer.

Authors:  Daniel P Hollern; Jordan Honeysett; Robert D Cardiff; Eran R Andrechek
Journal:  Mol Cell Biol       Date:  2014-06-16       Impact factor: 4.272

8.  Chordin-Like 1 Suppresses Bone Morphogenetic Protein 4-Induced Breast Cancer Cell Migration and Invasion.

Authors:  Chanèle Cyr-Depauw; Jason J Northey; Sébastien Tabariès; Matthew G Annis; Zhifeng Dong; Sean Cory; Michael Hallett; Jonathan P Rennhack; Eran R Andrechek; Peter M Siegel
Journal:  Mol Cell Biol       Date:  2016-05-02       Impact factor: 4.272

9.  Overexpression of the BMP4/SMAD signaling pathway in skull base chordomas is associated with poor prognosis.

Authors:  Yanjun Feng; Qiuhang Zhang; Zhenlin Wang; Bo Yan; Wei Wei; Pu Li
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

Review 10.  Genetics of breast cancer bone metastasis: a sequential multistep pattern.

Authors:  Hassan Fazilaty; Parvin Mehdipour
Journal:  Clin Exp Metastasis       Date:  2014-02-04       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.